trending Market Intelligence /marketintelligence/en/news-insights/trending/bv1lckit-5k8jz_77tv3oa2 content esgSubNav
In This List

MabVax Therapeutics gets another Nasdaq noncompliance notice

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


MabVax Therapeutics gets another Nasdaq noncompliance notice

MabVax Therapeutics Holdings Inc. said it fell out of compliance with Nasdaq's listing rule for the timely filing of periodic reports with the U.S. Securities and Exchange Commission.

The company is undergoing an SEC review over the reliability of its financial and registration statements.

The exchange's Listing Qualifications Department notified the San Diego-based developer of cancer therapies, whose quarterly filing for the period ended March 31 was delayed, that it has 60 days to submit either the periodic report or a plan to regain compliance.

If it submits a plan, the company could be granted up to 180 days, or until Nov. 12, to regain compliance.

The noncompliance notice has no impact on MabVax Therapeutics' Nasdaq listing. The company also recently fell out of compliance with Nasdaq's $2.5 million stockholders' equity listing requirement.